Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention
Molecules · 2025
DOI: 10.3390/molecules30020305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Xiaohua Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Environmental Ecology and Biological Engineering, Wuhan Institute of Technology, Wuhan 430205, China. Hauptthemen laut MEDLINE: Prodrugs, Fluorescent Dyes, Polyethylene Glycols, Estrogen Receptor alpha. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Fundamental Research Funds for the Central Universities of China, Fundamental Research Funds for the Central Universities of China, Excellent Young and Middle-aged Scientific and Technological Innovation Team Program of Hubei Province.
Abstract (Originalsprache)
In recent years, the near-infrared (NIR) fluorescence theranostic system has garnered increasing attention for its advantages in the simultaneous diagnosis- and imaging-guided delivery of therapeutic drugs. However, challenges such as strong background fluorescence signals and rapid metabolism have hindered the achievement of sufficient contrast between tumors and surrounding tissues, limiting the system’s applicability. This study aims to integrate the pegylation strategy with a tumor microenvironment-responsive approach. A novel esterase-activated EPR strategy prodrug, OBHSA-PEG-DCM, was designed. This prodrug links OBHSA, a protein degrader capable of efficient ERα protein degradation, to the PEG-modified fluorescent group (dicyanomethylene-4H-pyran, DCM) via an ester bond. This integration facilitates targeted drug delivery and enhances the retention of the fluorescent group within the tumor, allowing distinct in vivo tumor imaging periods. Experimental results show that, benefiting from overexpressed esterase in cancer cells, OBHSA-PEG-DCM can be efficiently hydrolyzed, releasing OBHSA and pegylated DCM. OBHSA demonstrated potent inhibition against MCF-7 cells (IC50 = 1.09 μM). Simultaneously, pegylated DCM exhibited remarkable in vivo imaging capabilities, lasting up to 12 days in mice, due to the enhanced permeability and retention (EPR) effect. OBHSA-PEG-DCM holds promise as a theranostic agent for ERα-positive breast cancer, offering both therapeutic and diagnostic capabilities. Importantly, this study highlights the utility of pegylated NIR fluorophores for long-circulating drug delivery systems, addressing current challenges in achieving high-contrast tumor imaging and effective targeted drug release.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Environmental Ecology and Biological Engineering, Wuhan Institute of Technology, Wuhan 430205, China.
- College of Life Sciences, Wuchang University of Technology, Wuhan 430223, China.
- Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China.
- State Key Laboratory of Virology and Biosafety, Frontier Science Center for Immunology and Metabolism, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, China.
ORCID-Profile: Xiaohua Wang, Guoyuan Hu, Hai-Bing Zhou
Förderung
- the Fundamental Research Funds for the Central Universities of China
- Fundamental Research Funds for the Central Universities of China
- Excellent Young and Middle-aged Scientific and Technological Innovation Team Program of Hubei Province
- Research and Development Fund of Wuchang University of Technology
Zitieren
APA
Wang, X., Deng, X., Xin, L., Dong, C., Hu, G., & Zhou, H. B. (2025). Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention. Molecules. https://doi.org/10.3390/molecules30020305
Vancouver
Wang X, Deng X, Xin L, Dong C, Hu G, Zhou HB. Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention. Molecules. 2025. doi:10.3390/molecules30020305
BibTeX
@article{Wang2025,
author = {Wang, Xiaohua and Deng, Xiaofei and Xin, Lilan and Dong, Chune and Hu, Guoyuan and Zhou, Hai-Bing},
title = {Pegylated NIR Fluorophore-Conjugated OBHSA Prodrug for ERα-Targeted Theranostics with Enhanced Imaging and Long-Term Retention},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30020305}
}
EUVIMED